ARTV Company Profile and Key Details

Artiva Biotherapeutics, Inc. has 24.54 million shares outstanding. The public float is 4.57 million shares, elevated short interest at 3.95% of float. This equals 391.10 thousand shares. The short ratio is 0.15 days. Institutional investors hold 97.58% of the float. Insiders own 24.05%. venBio Global Strategic Fund III, L.P. holds 1.94 million shares, GC Corp. has 1.26 million shares and Huh Yong-Jun has 1.26 million shares. Over the past six months, insider transactions show net selling. They sold 60.56 thousand shares across 4 transactions.

Short-term trend indicators are bearishly aligned (SMA20 -13.93%, SMA50 -7.53%, SMA200 25.37%). The stock’s 14-day RSI is 41.61 (neutral), while the ATR of 0.39 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -47.42% below its high and over 163.27% above its low. Average 10-day trading volume of 197.04 thousand shares is below the 3-month average of 1.01 million, indicating normal recent market interest.

Artiva Biotherapeutics, Inc. generated EPS of -$3.25 over the past year. Five-year average earnings growth is -64.01%. Wall Street analysts project EPS growth of 24.02% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $15.00. The high target offers 494.32% upside. The low target suggests 287.6% downside. The mean target is $20.00. This offers 416.8% upside. Artiva Biotherapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -4.42%. The prior quarter beat by 3.57%. Over the last six quarters, Apple has recorded several small beats. These include 334.09% in August 29, 2024.

Artiva Biotherapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.85. This means the shares are trading above this model’s fair value.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) shares are flat 7.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Artiva Biotherapeutics, Inc. trading at a premium to the broader market with a P/E of -1.31. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.38, suggesting 426.61% upside. Our AI forecast model points to short-term strength (0.78% over two weeks), a medium-term rise (19.9% over three months), and a longer-term gain (217.57% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Artiva Biotherapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.78%, with price expected at $3.90 by February 19, 2026, within a range of $3.42 to $4.42 3-Month Outlook: Projected rise of 19.9%, reaching $4.64 by May 05, 2026, with a range of $4.25 to $5.03. 1-Year Outlook: Projected gain of 217.57%, with price at $12.29 by February 05, 2027, within a range of $7.57 to $15.44.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) closed at $3.87 USD, losing -$0.15 (-3.73%) from the previous close of $4.02. The stock is currently mid-range between its 52-week high and low $1.47 and $7.36. With a market capitalization of about $94.99 million, Artiva Biotherapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.95). Key stats such as the average daily volume over the past year has been around 1.05 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Artiva Biotherapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Fred Aslan, the company employs approximately 96 people and listed since July 19, 2024. Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.

Artiva Biotherapeutics, Inc. trades at a P/E ratio of -1.31, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.73 suggesting the stock is closer to book value. The P/FCF stands at -1.2, also above market averages.